A pilot assessment was conducted to test the first version of the HTA Core Model and the draft Guidelines for Rapid relative effectiveness assessment (REA) of pharmaceuticals, as well as the capacity for international collaboration required to produce an assessment. The aim of the present study was to describe and analyze the lessons learned from the pilot project based on input from three different perspectives: the assessors, the users (HTA organizations) and the marketing authorization holder (MAH). This article does not address the scientific quality of the pilot report.
Kleijnen, S., Pasternack, I., Vuola, J., Van De Casteele, M., Bucsics, A., Pulis, I., Dibidino, R., Sacchini, D., Montilla, S., Abrishami, P., Sammut, S., Muscolo, L., Happonen, P., Goettsch, W., Piloting international production of rapid relative effectiveness assessments of pharmaceuticals, <<INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE>>, 2014; 30 (5): 521-529. [doi:10.1017/S0266462314000622] [http://hdl.handle.net/10807/64947]
Piloting international production of rapid relative effectiveness assessments of pharmaceuticals
Sacchini, Dario;
2015
Abstract
A pilot assessment was conducted to test the first version of the HTA Core Model and the draft Guidelines for Rapid relative effectiveness assessment (REA) of pharmaceuticals, as well as the capacity for international collaboration required to produce an assessment. The aim of the present study was to describe and analyze the lessons learned from the pilot project based on input from three different perspectives: the assessors, the users (HTA organizations) and the marketing authorization holder (MAH). This article does not address the scientific quality of the pilot report.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
